{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:11:41Z","timestamp":1791216701835,"version":"4.1.0"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"crossref","award":["IST-JPN-000230"],"award-info":[{"award-number":["IST-JPN-000230"]}],"id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Polycystic liver disease (PLD) is a common extrarenal complication of autosomal dominant polycystic kidney disease (ADPKD), which causes compression-related syndrome and ultimately leads to liver dysfunction. Tolvaptan, a V2 receptor antagonist, is widely used to protect kidney function in ADPKD but its effect on PLD remains unknown. An observational cohort study was conducted to evaluate tolvaptan\u2019s effect on patients with PLD due to ADPKD. After screening 902 patients, we found the 107 ADPKD patients with PLD who met the criteria of tolvaptan use in Japan. Among them, tolvaptan was prescribed for 62 patients (tolvaptan group), while the other was defined as the non-tolvaptan group. Compared with the non-tolvaptan group, the tolvaptan group had larger height-adjusted total kidney volume (median 994(range 450\u20134152) mL\/m, 513 (405\u20131928) mL\/m, p = 0.01), lower albumin level (mean 3.9\u00b1SD 0.4 g\/dL, 4.3\u00b10.4g\/dL, p&lt;0.01), and higher serum creatinine level (1.2\u00b10.4 mg\/dL, 0.9\u00b10.2 mg\/dL, p&lt;0.01). Although the median change in annual growth rate of total liver volume (TLV) was not statistically different between the tolvaptan group (-0.8 (-15.9, 16.7) %\/year) and the non-tolvaptan group (1.7 (-15.6\u201318.7) %\/year)(p = 0.52), 20 (43.5%) patients in the tolvaptan group experienced a decrease in the growth rate of TLV (responders). A multivariable logistic regression model adjusting for related variables showed that older age (odds ratio 1.15 [95% CI 1.01\u20131.32]) and a higher growth rate of TLV in the non-tolvaptan period (odds 1.45 95% CI 1.10\u20131.90) were significantly associated with responders. In conclusion, the change in annual growth rate of TLV in ADPKD patients taking tolvaptan was not statistically different compared with that in ADPKD patients without taking tolvaptan. However, tolvaptan may have the potential to suppress the growth rate of TLV in some PLD patients due to ADPKD, especially in older patients or those that are rapid progressors of PLD. Several limitations were included in this study, therefore well-designed prospective studies were required to confirm the effect of tolvaptan on PLD.<\/jats:p>","DOI":"10.1371\/journal.pone.0264065","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T18:40:28Z","timestamp":1645123228000},"page":"e0264065","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4187-1067","authenticated-orcid":true,"given":"Hiroki","family":"Mizuno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinari","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Suwabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ikuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Yamanouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiko","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Ubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"issue":"6","key":"pone.0264065.ref001","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1002\/hep.24036","article-title":"Medical and surgical treatment options for polycystic liver disease","volume":"52","author":"JPH Drenth","year":"2010","journal-title":"Hepatology"},{"issue":"1","key":"pone.0264065.ref002","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/tri.12875","article-title":"Center is an important indicator for choice of invasive therapy in polycystic liver disease","volume":"30","author":"HMA D\u2019Agnolo","year":"2017","journal-title":"Transpl Int"},{"issue":"4","key":"pone.0264065.ref003","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/ndt\/gfx188","article-title":"Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial","volume":"33","author":"E Cornec-Le Gall","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"pone.0264065.ref004","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2215\/CJN.00080605","article-title":"Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort","volume":"1","author":"KT Bae","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"pone.0264065.ref005","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrgastro.2012.254","article-title":"Diagnosis and management of polycystic liver disease","volume":"10","author":"TJ Gevers","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"pone.0264065.ref006","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/apt.13301","article-title":"Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomized, placebo-controlled trials","volume":"42","author":"MK Neijenhuis","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"pone.0264065.ref007","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.mayocp.2015.05.011","article-title":"Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease","volume":"90","author":"MC Hogan","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"pone.0264065.ref008","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/ndt\/gfw008","article-title":"Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease","volume":"31","author":"FT Chebib","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"pone.0264065.ref009","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1053\/j.gastro.2013.04.055","article-title":"Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data","volume":"145","author":"TJ Gevers","year":"2013","journal-title":"Gastroenterology"},{"issue":"2","key":"pone.0264065.ref010","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1148\/radiology.190.2.8284385","article-title":"Symptomatic hepatic cysts: percutaneous drainage and sclerosis","volume":"190","author":"E vanSonnenberg","year":"1994","journal-title":"Radiology"},{"issue":"3","key":"pone.0264065.ref011","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00464-018-6490-8","article-title":"Clinical response after laparoscopic fenestration of symptomatic hepatic cysts: a systematic review and meta-analysis","volume":"33","author":"LHP Bernts","year":"2019","journal-title":"Surg Endosc"},{"issue":"6","key":"pone.0264065.ref012","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/j.ajkd.2014.01.422","article-title":"Intravascular embolization therapy in patients with enlarged polycystic liver","volume":"63","author":"J Hoshino","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"pone.0264065.ref013","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2019.04.018","article-title":"Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease","volume":"157","author":"RMM van Aerts","year":"2019","journal-title":"Gastroenterology"},{"issue":"5","key":"pone.0264065.ref014","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/liv.12726","article-title":"Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial","volume":"35","author":"TJG Gevers","year":"2015","journal-title":"Liver Int"},{"issue":"9","key":"pone.0264065.ref015","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/ndt\/gfs152","article-title":"Somatostatin analog therapy for severe polycystic liver disease: results after 2 years","volume":"27","author":"MC Hogan","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"pone.0264065.ref016","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2036.2011.04923.x","article-title":"The long-term outcome of patients with polycystic liver disease treated with lanreotide","volume":"35","author":"M Chrispijn","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"pone.0264065.ref017","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"MC Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"pone.0264065.ref018","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial","volume":"137","author":"L van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"issue":"20","key":"pone.0264065.ref019","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease","volume":"377","author":"VE Torres","year":"2017","journal-title":"N Engl J Med"},{"issue":"25","key":"pone.0264065.ref020","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"VE Torres","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0264065.ref021","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12882-019-1290-5","article-title":"Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model","volume":"20","author":"H Bennett","year":"2019","journal-title":"BMC Nephrol"},{"issue":"3","key":"pone.0264065.ref022","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000477664","article-title":"Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease","volume":"7","author":"H Mizuno","year":"2017","journal-title":"Case Rep Nephrol Dial"},{"issue":"1","key":"pone.0264065.ref023","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3350\/cmh.2019.0026","article-title":"The management of polycystic liver disease by tolvaptan","volume":"26","author":"T Takenaka","year":"2020","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"pone.0264065.ref024","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of ADPKD","volume":"20","author":"Y Pei","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"pone.0264065.ref025","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"S Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"pone.0264065.ref026","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.bbrc.2020.01.142","article-title":"Upregulation of renal Na-K-2Cl cotransporter 2 in obese diabetes mellitus via a vasopressin receptor 2-dependent pathway","volume":"524","author":"K Sakai","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"pone.0264065.ref027","doi-asserted-by":"crossref","first-page":"F1166","DOI":"10.1152\/ajprenal.00196.2007","article-title":"Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL","volume":"293","author":"K Mutig","journal-title":"Am J Physiol Renal Physiiol"},{"issue":"1","key":"pone.0264065.ref028","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"VE Torres","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"pone.0264065.ref029","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/labinvest.2016.93","article-title":"Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease","volume":"96","author":"R Mancinelli","year":"2016","journal-title":"Lab Invest"},{"issue":"5","key":"pone.0264065.ref030","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2215\/CJN.06300615","article-title":"Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial","volume":"11","author":"VE Torres","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"pone.0264065.ref031","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ekir.2016.08.001","article-title":"Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial","volume":"1","author":"MV Irazabal","year":"2016","journal-title":"Kidney Int Rep"},{"issue":"6","key":"pone.0264065.ref032","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1053\/gast.2000.20184","article-title":"Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats","volume":"119","author":"D Alvaro","year":"2000","journal-title":"Gastroenterology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0264065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T18:41:02Z","timestamp":1645123262000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0264065"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Shimosawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0264065","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]}}}